What does GHK-Cu stand for?

GHK-Cu means glycine, histidine and lysine bound to copper. G, H and K are the standard one-letter codes for those three amino acids, and Cu is the chemical symbol for copper. Early papers abbreviated it GHL. Chemical databases list the peptide as prezatide, and skin-care labels usually call the copper form copper tripeptide-1.

Where does GHK-Cu come from?

The body makes it. GHK was first found in human blood serum, and Pickart's reviews also describe it in saliva and urine. The GHK-Cu in creams and vials is made synthetically; a lab-made version of the tripeptide was reported as early as 1973. Finding a molecule in blood does not show what an added amount does in a person.

Is GHK-Cu the same as AHK-Cu?

No. AHK-Cu swaps glycine for alanine, which makes it a different copper peptide. A widely quoted 2007 study of human hair follicles grown outside the body tested AHK-Cu, not GHK-Cu, under a title that says only tripeptide-copper complex. Results from one molecule cannot be credited to the other.

When was GHK-Cu first tested in people?

The clearest early human trial was published in 1994. It was a multicenter randomized trial of a topical GHK-Cu gel on diabetic foot ulcers, given alongside standardized wound care, and the authors reported more ulcer closure than with an inactive gel. As a single trial of a gel on open wounds, it says nothing about injected GHK-Cu.

Is GHK-Cu FDA-approved?

No. GHK-Cu is not FDA-approved for any use, and the compounded formulation offered here is not FDA-approved. FDA's May 14, 2026 list places non-injectable GHK-Cu under evaluation for compounding, and an advisory committee discussion is planned before the end of February 2027. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

Who Discovered GHK-Cu? Loren Pickart, in 1973

Who discovered GHK-Cu? Loren Pickart did. In 1973, in work tied to his doctorate at the University of California, San Francisco, he and M. Michael Thaler reported a tiny peptide in human blood serum that helped liver cells survive. Over the next seven years Pickart and his colleagues pinned down its three building blocks (glycine, histidine and lysine) and showed that it grabs onto copper. That copper-bound form is what people now call GHK-Cu.

The discovery is well documented. What the molecule does in a living person is far less settled.

Who discovered GHK-Cu, and what was he looking for?

Pickart's starting point was aging. As he later described it, liver tissue from older people, when bathed in plasma from young people, started making proteins in a pattern more like young tissue. Something in young blood seemed to carry a signal, and he went looking for it (Pickart and Margolina, 2018).

The first published report reads more narrowly. A May 1973 paper in Nature New Biology was titled "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver". A tripeptide is a chain of three amino acids, and neoplastic means cancerous: the factor helped normal liver cells live longer and spurred liver-tumor cells to grow.

That September, the team reported that a lab-made tripeptide had the same kind of effect (Biochemical and Biophysical Research Communications, 1973). The sequence followed in 1977, under a title that says it outright: "Growth-modulating serum tripeptide is glycyl-histidyl-lysine" (Experientia, 1977).

All of this was laboratory work on cells and tissue, not tests in people.

How GHK-Cu got its name

The name is the recipe. G, H and K are the standard one-letter codes for glycine, histidine and lysine, and Cu is the chemical symbol for copper. Early papers wrote it GHL, from the first letters of the amino acids; the field settled on GHK because in the one-letter code, L already belongs to leucine.

Chemical databases also list the peptide as prezatide and even "liver cell growth factor", a nod to where it started (PubChem). On skin-care labels the copper form is usually copper tripeptide-1 (PubChem).

One look-alike to keep separate is AHK-Cu, which swaps glycine for alanine. A 2007 hair-follicle study that often gets quoted for GHK-Cu actually tested AHK-Cu, under a title that says only "tripeptide-copper complex" (Archives of Pharmacal Research, 2007). The hair question has its own page: GHK-Cu for hair growth.

When copper entered the story

In February 1980, Pickart and Thaler reported that in blood the peptide is bound to copper and iron, and that it seems to act as a peptide-metal pair in cell culture (Journal of Cellular Physiology, 1980).

A December 1980 paper in Nature, written from the Virginia Mason Research Center in Seattle with University of Washington and Albert Einstein College of Medicine colleagues, went further. The peptide kept coming out of purification alongside roughly equal amounts of copper. The team showed it readily binds copper and raises how much copper cultured liver-tumor cells take in, and proposed it might work as a copper carrier (Nature, 1980).

How strong is that grip? A 1981 study set the peptide against albumin, the main copper-carrying protein in blood. With equal amounts of the two, about 42% of the copper ended up on the peptide (Lau and Sarkar, Biochemical Journal, 1981).

From liver cells to skin and wounds

The turn toward skin came in the late 1980s. A team at the medical faculty in Reims, France, with Pickart as a co-author, reported in 1988 that GHK-Cu raised collagen production by fibroblasts, the cells that build skin's supporting scaffold, grown in culture (FEBS Letters, 1988). They also pointed out that the GHK sequence sits inside type I collagen itself and suggested it might be released at a wound. That was an idea, not a measurement.

The group then moved to animals. In rats, small mesh chambers placed under the skin built up more collagen when GHK-Cu was injected into them (Journal of Clinical Investigation, 1993). That is an artificial rat-wound model: it explains the interest, not what happens in a person.

By then the idea had a commercial home. Pickart is the named inventor on a US patent for using the copper complex in wound healing, issued July 26, 1988 and assigned that year to ProCyte Corporation, a Washington company (US 4,760,051).

The first human data

The clearest early human trial came from wound care. A 1994 multicenter randomized trial, meaning patients were assigned to a group by chance, tested a GHK-Cu gel called Iamin Gel on diabetic foot ulcers, alongside standardized wound care for everyone. The authors reported more ulcer closure with the copper gel than with an inactive gel (Wound Repair and Regeneration, 1994). It was one trial of a gel on open wounds, and it says nothing about an injection.

What reached the US market was cleared as a device, not approved as a drug. FDA's device database records ProCyte's Iamin Gel Wound Dressing as cleared on February 5, 1996 through the 510(k) route, for devices substantially equivalent to ones already sold (FDA, K953853). A 1997 summary for a follow-up gel lists prezatide copper acetate among its ingredients and describes a dressing that keeps a wound moist and protected (FDA, K970153).

From face creams to injectable vials

Skin care is where most people met GHK-Cu; Pickart's 2018 review calls it "widely used in skin and hair products" (International Journal of Molecular Sciences, 2018). The small facial studies behind that market, and their limits, are covered in what GHK-Cu does.

The newest chapter is injections. GHK-Cu now turns up in vials sold online with no prescription, and in compounded injectable blends such as KLOW, which pairs it with BPC-157, TB-500 and KPV. A cream on the skin and a shot beneath it are different exposures; evidence from one doesn't transfer to the other.

Where GHK-Cu stands today

As of September 22, 2026, the day this article was written, GHK-Cu has never had a US-approved product, and the compounded formulation offered here is not FDA-approved. FDA's list of nominated compounding ingredients, marked "Updated May 14, 2026", places GHK-Cu for non-injectable routes in Category 1, meaning under evaluation, and records that the injectable-route nomination was withdrawn (FDA). FDA's meeting page says its compounding advisory committee will discuss GHK-Cu before the end of February 2027, with the time and place still to be scheduled (FDA). The step-by-step history is in why GHK-Cu is not FDA-approved.

A systematic review published August 20, 2026 found 20 eligible studies of GHK-Cu in aesthetic medicine: 18 in cells or animals and just 2 randomized human trials. The authors called for larger, standardized trials (Aesthetic Surgery Journal, 2026). The GHK-Cu clinical evidence guide walks through what those two trials measured.

Neither of those decides an individual case. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

What the history means for a prescription today

It helps to know who wrote much of this history. Many of the most-quoted GHK-Cu summaries are reviews by Pickart himself, so it pays to check which claims rest on independent studies. The familiar age curve, about 200 ng/mL of GHK in blood at age 20 falling to about 80 ng/mL by 60, is reported in those same reviews (BioMed Research International, 2015).

Fifty-three years on, GHK-Cu has one of the better-documented origin stories among peptides: a named researcher, dated papers and a clear line from liver cells to copper to skin. What it doesn't supply is a large human trial of the injected form.

A prescription can't fill that gap, but it changes who is accountable. A vial bought online without one has no clinician reading your history and no pharmacy record behind it. At Promise, a licensed provider reviews every request and not everyone qualifies; when GHK-Cu is prescribed, a licensed U.S. compounding pharmacy prepares it for that patient by name.